Literature DB >> 12458677

Transepithelial transport of prodrugs of the HIV protease inhibitors saquinavir, indinavir, and nelfinavir across Caco-2 cell monolayers.

Marielle Rouquayrol1, Bérangère Gaucher, Dominique Roche, Jacques Greiner, Pierre Vierling.   

Abstract

PURPOSE: [corrected] This study is dedicated to the permeation of various amino acid-, D-glucose-, and PEG-conjugates of indinavir, saquinavir, and nelfinavir across monolayers of Caco-2 cells as models of the intestinal barrier. This screening is aimed at detecting the most promising prodrugs for improving the intestinal absorption of these protease inhibitors.
METHODS: The bidirectional transport of the prodrugs was investigated using P-gp-expressing Caco-2 monolayers grown on membrane inserts using high-performance liquid chromatography for quantitation.
RESULTS: The L-valyl, L-leucyl, and L-phenylalanyl ester conjugates led to an enhancement of the absorptive flux of indinavir or saquinavir. These results are likely attributable to an active transport mechanism and/or to a decrease of their efflux by carriers such as P-gp. Connection of tyrosine through its hydroxyl, of D-glucose, or of polyethylene glycol decreased their absorptive and secretory diffusion.
CONCLUSIONS: Conjugation of the protease inhibitors to amino acids constitutes a most appealing alternative that could improve their intestinal absorption and oral bioavailability. Whether it could improve their delivery into the central nervous system remains to be explored. D-Glucose conjugation will most probably not improve their intestinal absorption or their crossing of the blood-brain barrier. If some pharmacologic benefits are to be expected from PEG-protease inhibitor conjugates, they must then be administered intravenously.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12458677     DOI: 10.1023/a:1020913631309

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  16 in total

Review 1.  Transporter-mediated permeation of drugs across the blood-brain barrier.

Authors:  I Tamai; A Tsuji
Journal:  J Pharm Sci       Date:  2000-11       Impact factor: 3.534

Review 2.  Prodrug approaches to the improved delivery of peptide drugs.

Authors:  W Wang; J Jiang; C E Ballard; B Wang
Journal:  Curr Pharm Des       Date:  1999-04       Impact factor: 3.116

3.  Investigation of distribution, transport and uptake of anti-HIV drugs to the central nervous system.

Authors: 
Journal:  Adv Drug Deliv Rev       Date:  1999-10-18       Impact factor: 15.470

Review 4.  Cell cultures as models for drug absorption across the intestinal mucosa.

Authors:  P Artursson
Journal:  Crit Rev Ther Drug Carrier Syst       Date:  1991       Impact factor: 4.889

Review 5.  Clinical pharmacology of HIV protease inhibitors: focus on saquinavir, indinavir, and ritonavir.

Authors:  R M Hoetelmans; P L Meenhorst; J W Mulder; D M Burger; C H Koks; J H Beijnen
Journal:  Pharm World Sci       Date:  1997-08

Review 6.  Targeting HIV-1 protease: a test of drug-design methodologies.

Authors:  M L West; D P Fairlie
Journal:  Trends Pharmacol Sci       Date:  1995-02       Impact factor: 14.819

7.  The influence of donor and reservoir additives on Caco-2 permeability and secretory transport of HIV protease inhibitors and other lipophilic compounds.

Authors:  B J Aungst; N H Nguyen; J P Bulgarelli; K Oates-Lenz
Journal:  Pharm Res       Date:  2000-10       Impact factor: 4.200

8.  Comparison of the disposition of ester prodrugs of the antiviral agent 9-(2-phosphonylmethoxyethyl)adenine [PMEA] in Caco-2 monolayers.

Authors:  P Annaert; G Gosselin; A Pompon; S Benzaria; G Valette; J L Imbach; L Naesens; S Hatse; E de Clercq; G Van den Mooter; R Kinget; P Augustijns
Journal:  Pharm Res       Date:  1998-02       Impact factor: 4.200

9.  Age-dependent expression of P-glycoprotein gp170 in Caco-2 cell monolayers.

Authors:  K I Hosoya; K J Kim; V H Lee
Journal:  Pharm Res       Date:  1996-06       Impact factor: 4.200

Review 10.  Human immunodeficiency virus protease inhibitors.

Authors:  K Z Rana; M N Dudley
Journal:  Pharmacotherapy       Date:  1999-01       Impact factor: 4.705

View more
  8 in total

1.  Intestinal absorption of novel-dipeptide prodrugs of saquinavir in rats.

Authors:  Ritesh Jain; Sridhar Duvvuri; Viral Kansara; Nanda Kishore Mandava; Ashim K Mitra
Journal:  Int J Pharm       Date:  2006-12-03       Impact factor: 5.875

2.  FK506-binding protein (FKBP) partitions a modified HIV protease inhibitor into blood cells and prolongs its lifetime in vivo.

Authors:  Paul S Marinec; Lei Chen; Kenneth J Barr; Mitchell W Mutz; Gerald R Crabtree; Jason E Gestwicki
Journal:  Proc Natl Acad Sci U S A       Date:  2009-01-21       Impact factor: 11.205

3.  Targeting SVCT for enhanced drug absorption: synthesis and in vitro evaluation of a novel vitamin C conjugated prodrug of saquinavir.

Authors:  Shuanghui Luo; Zhiying Wang; Mitesh Patel; Varun Khurana; Xiaodong Zhu; Dhananjay Pal; Ashim K Mitra
Journal:  Int J Pharm       Date:  2011-05-07       Impact factor: 5.875

Review 4.  Clinical Implications of P-Glycoprotein Modulation in Drug-Drug Interactions.

Authors:  Marie Lund; Tonny Studsgaard Petersen; Kim Peder Dalhoff
Journal:  Drugs       Date:  2017-05       Impact factor: 9.546

5.  Functional characterization of peptide transporters in MDCKII-MDR1 cell line as a model for oral absorption studies.

Authors:  Sheetal Agarwal; Ritesh Jain; Dhananjay Pal; Ashim K Mitra
Journal:  Int J Pharm       Date:  2006-10-10       Impact factor: 5.875

6.  Montelukast is a potent and durable inhibitor of multidrug resistance protein 2-mediated efflux of taxol and saquinavir.

Authors:  Upal Roy; Geetika Chakravarty; Kerstin Honer Zu Bentrup; Debasis Mondal
Journal:  Biol Pharm Bull       Date:  2009-12       Impact factor: 2.233

7.  Biocompatibility Profile and In Vitro Cellular Uptake of Self-assembled Alginate Nanoparticles.

Authors:  Pei Zhang; Shirui Zhao; Yaoyao Yu; Huan Wang; Yan Yang; Chenguang Liu
Journal:  Molecules       Date:  2019-02-03       Impact factor: 4.411

8.  Evaluation of Marine Diindolinonepyrane in Vitro and in Vivo: Permeability Characterization in Caco-2 Cells Monolayer and Pharmacokinetic Properties in Beagle Dogs.

Authors:  Zibin Ma; Ruihua Guo; Jeevithan Elango; Bin Bao; Wenhui Wu
Journal:  Mar Drugs       Date:  2019-11-20       Impact factor: 5.118

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.